# FDA 483 - Philip NMI Raskin - January 11, 2024

Source: https://www.globalkeysolutions.net/records/483/philip-nmi-raskin/409f2a22-c835-4ea3-a8ed-4bc4a0b41d36

> FDA 483 for Philip NMI Raskin on January 11, 2024. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Philip NMI Raskin
- Inspection Date: 2024-01-11
- Product Type: drugs
- Office Name: Division of Human and Animal Food Operations - West III
- Summary: An FDA inspection of Philip NMI Raskin, MD, Clinical Investigator in Dallas, TX, revealed that an investigation was not conducted in accordance with the investigational plan. Specifically, the study drug was not suspended for subjects experiencing adverse events as required by the protocol. This indicates a significant deviation from established study procedures.

## Related Officers

- [Ruth E. Medcalf](https://www.globalkeysolutions.net/people/ruth-e-medcalf/71a61d32-807b-4b73-9ea7-b59287e14e56)
- [investigator](https://www.globalkeysolutions.net/people/travis-m-beard/a89f6d0b-dc5b-4adc-84f5-36e04b00fc2d)

Company: https://www.globalkeysolutions.net/companies/philip-nmi-raskin/9074ba12-52ed-4918-8a4e-7fbcab7f7974

Office: https://www.globalkeysolutions.net/offices/division-of-human-and-animal-food-operations-west-iii/2cda09a5-06c4-433f-9df0-0d7903a6efab